NPC(SH:600713) Xin Lang Zheng Quan·2025-10-09 17:20Core Viewpoint - Nanjing Pharmaceutical has announced the progress of its share repurchase plan, which aims to utilize self-owned or raised funds to buy back shares for the implementation of its 2025 restricted stock incentive plan [2][3]. Summary by Sections Repurchase Plan Overview - On March 14, 2025, Nanjing Pharmaceutical's board approved a share repurchase plan, with the first disclosure on March 15, 2025. The repurchase period is set from March 14, 2025, to March 14, 2026. The expected repurchase amount is between 70 million yuan (approximately 10.1 million USD) and 131.58 million yuan (approximately 18.8 million USD), with a maximum repurchase price of 7.31 yuan (approximately 1.05 USD) per share [2]. Repurchase Progress Details - As of the announcement date, the company has repurchased a total of 16,299,951 shares, accounting for 1.25% of the total share capital, with a cumulative repurchase amount of 80.2576 million yuan (approximately 11.5 million USD). The actual repurchase price ranged from 4.69 yuan (approximately 0.67 USD) to 5.22 yuan (approximately 0.75 USD) per share. The total share capital increased from 1,308,928,704 shares at the end of August 2025 to 1,308,929,289 shares at the end of September 2025 due to the conversion of convertible bonds [3]. Future Plans - Nanjing Pharmaceutical will adhere to relevant regulations and guidelines during the repurchase period and will make repurchase decisions based on market conditions while fulfilling its information disclosure obligations in a timely manner [4].